AIM 1. Establish a multicenter Vasculitis clinical Research Network (VCRN) to foster and facilitate clinical investigation in the inflammatory vasculitides. The 4 major US vasculitis centers (Boston University, Cleveland Clinic, Johns Hopkins, and Mayo Clinic) will combine their clinical and research expertise with the resources of the General Clinical Research Centers at each site to form the core of the Network. Additionally, the combined strengths of several domestic and foreign secondary centers will be incorporated into the Network. The VCRN would serve as the focal point for vasculitis research in the United States and internationally for both clinical investigators and patients. To achieve this aim, the following activities are proposed: 1.1 Develop a clinical data repository in collaboration with other Rare Disease Clinical Research Networks and the Rare Disease Data and Technology Coordinating Center. 1.2 Build a vasculitis clinical specimen bank for storage of serum, plasma, DNA and tissue samples linked to the clinical data repository. 1.3 Enact a national recruitment program in cooperation with various vasculitis patient advocacy groups. 1.4 Utilize the extensive resources of the General Clinical Research Centers at each Primary Network Site AIM 2. Conduct a series of related longitudinal studies of novel biomarkers of vasculitis disease activity. Utilizing the VCRN Clinical Data Repository and Clinical Specimen Bank and in coordination with biostatistical support from the Data and Technology Coordinating Center, the VCRN Biomarkers Project will use several promising techniques to develop new markers of disease activity including: 2.1 Proteomics 2.2 Molecular Markers of Oxidative Stress and Inflammation 2.3 Additionally, this program will be established in a fashion that would easily allow for testing of future novel biomarkers by investigators both within and beyond the Network.
AIM 3. Utilize the VCRN and patient base to conduct Phase I and II clinical trials within the proposed grant period and create the infrastructure to greatly facilitate the design and performance of other future trials.
AIM 4. Establish the Vasculitis Clinical Investigator Fellowship as a core mission on the VCRN to provide a mechanism to support, train, and mentor fellows interested in establishing academic careers focused on vasculitis research.
This aim will address the pressing need in academic medicine for the training and retaining of patient oriented clinical investigators.
AIM 5. Build and contribute to an electronic website resource with substantive content for clinicians, researchers, and patients.
| Springer, Jason Michael; Monach, Paul; Cuthbertson, David et al. (2018) Serum S100 Proteins as a Marker of Disease Activity in Large Vessel Vasculitis. J Clin Rheumatol 24:393-395 |
| Robson, Joanna C; Dawson, Jill; Cronholm, Peter F et al. (2018) Health-related quality of life in ANCA-associated vasculitis and item generation for a disease-specific patient-reported outcome measure. Patient Relat Outcome Meas 9:17-34 |
| Grayson, Peter C; Eddy, Sean; Taroni, Jaclyn N et al. (2018) Metabolic pathways and immunometabolism in rare kidney diseases. Ann Rheum Dis 77:1226-1233 |
| Barra, Lillian; Borchin, Renée L; Burroughs, Cristina et al. (2018) Impact of vasculitis on employment and income. Clin Exp Rheumatol 36 Suppl 111:58-64 |
| Sreih, Antoine G; Ezzedine, Rana; Leng, Lin et al. (2018) Role of Macrophage Migration Inhibitory Factor in Granulomatosis With Polyangiitis. Arthritis Rheumatol 70:2077-2086 |
| Kermani, Tanaz A; Diab, Sehriban; Sreih, Antoine G et al. (2018) Arterial lesions in giant cell arteritis: A longitudinal study. Semin Arthritis Rheum : |
| Berti, Alvise; Warner, Roscoe; Johnson, Kent et al. (2018) Brief Report: Circulating Cytokine Profiles and Antineutrophil Cytoplasmic Antibody Specificity in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Rheumatol 70:1114-1121 |
| Robson, Joanna C; Dawson, Jill; Cronholm, Peter F et al. (2018) Patient perceptions of glucocorticoids in anti-neutrophil cytoplasmic antibody-associated vasculitis. Rheumatol Int 38:675-682 |
| Kermani, Tanaz A; Sreih, Antoine G; Cuthbertson, David et al. (2018) Evaluation of damage in giant cell arteritis. Rheumatology (Oxford) 57:322-328 |
| Robson, Joanna C; Tomasson, Gunnar; Milman, Nataliya et al. (2017) OMERACT Endorsement of Patient-reported Outcome Instruments in Antineutrophil Cytoplasmic Antibody-associated Vasculitis. J Rheumatol 44:1529-1535 |
Showing the most recent 10 out of 91 publications
